Form 4: Heron Therapeutics Director Susan Rodriguez Acquires Shares and Options

Director Susan Rodriguez of Heron Therapeutics acquired 17,950 shares of common stock and 35,900 stock options on January 30, 2025.

Summary

• Susan Rodriguez, a director at Heron Therapeutics, acquired 17,950 shares of common stock and 35,900 stock options on January 30, 2025.
• The common stock was granted as restricted stock units that will vest on January 30, 2026.
• Each restricted stock unit represents a contingent right to receive one share of common stock.
• The stock options vest in 12 equal monthly installments starting one month after the grant date and expire on January 30, 2035.
• The exercise price for the stock options is $1.73 per share.

Sentiment

Score: 6

Explanation: The document is a routine filing and does not contain any information that would significantly impact sentiment. The acquisition of shares and options by a director is a neutral to slightly positive event.

Positives

• The acquisition of shares and options by a director could be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard SEC Form 4 filing, which is common for company insiders who have made transactions in their company's stock. It is a routine disclosure required by law.

Comparison to Industry Standards

• Form 4 filings are a standard practice for publicly traded companies in the US, and this filing is consistent with those requirements.
• The vesting schedule for the restricted stock units and stock options is typical for executive compensation packages.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment due to the director's increased stake in the company.

Key Dates

Keywords

Heron Therapeutics, Director, Stock Options, Restricted Stock Units, Share Acquisition, Form 4, Insider Trading